Processing

Please wait...

Settings

Settings

1. WO2000042002 - SULPHOHYDROXAMIC ACIDS AND SULPHOHYDROXAMATES AND THEIR USE AS MEK INHIBITORS

Publication Number WO/2000/042002
Publication Date 20.07.2000
International Application No. PCT/US1999/030417
International Filing Date 21.12.1999
Chapter 2 Demand Filed 20.07.2000
IPC
C07C 311/39 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
311Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
30Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
37having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
38having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
39having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
CPC
A61P 17/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
06Antipsoriatics
A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
A61P 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
Applicants
  • WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road Morris Plains, NJ 07950, US (AllExceptUS)
  • TECLE, Haile [US/US]; US (UsOnly)
Inventors
  • TECLE, Haile; US
Agents
  • RYAN, M., Andrea; Warner-Lambert Company 201 Tabor Road Morris Plains, NJ 07950 , US
  • MANSMANN, Ivo Dr. Rudolf Tesch; Warner-Lambert Company Legal Division, Patent Dept. c/o Gödecke AG Mooswaldalle 1 D-79090 Freiburg, DE
Priority Data
60/115,65213.01.1999US
60/122,41702.03.1999US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SULPHOHYDROXAMIC ACIDS AND SULPHOHYDROXAMATES AND THEIR USE AS MEK INHIBITORS
(FR) ACIDES SULFO-HYDROXAMIQUES ET SULFO-HYDROXAMATES ET LEUR UTILISATION COMME INHIBITEURS MK
Abstract
(EN)
Sulfohydroxamic acid diarylamines of formula (I), in which the variables are as defined in the claims, are inhibitors of MEK and are effective in the treatment of proliferative diseases, cancer, stroke, heart failure, xenograft rejection, arthritis, cystic fibrosis, hepatomegaly, cardiomegaly, Alzheimer's disease, complications of diabetes, septic shock, and viral infection.
(FR)
L'invention concerne des diarylamines d'acide sulfo-hydroxamique de formule (I), dans laquelle les variables sont, telles qu'elles sont définies dans les revendications, des inhibiteurs de MEK et efficaces dans le traitement de maladies proliférantes, telles que cancer, accidents vasculaires cérébraux, défaillance cardiaque, rejet d'hétérogreffes, arthrite, fibrose cystique, hépatomégalie, cardiomégalie, maladie d'Alzheimer, complications du diabète, choc septique et infection virale.
Latest bibliographic data on file with the International Bureau